{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001112","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.165939+00:00","generated_at":"2026-06-12T04:33:40.673073+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan","bullets":["Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).","Cash, equivalents and restricted cash $380.6M at June 30; cash runway extended through early 2026.","ARCT-154 Phase 3 booster met primary endpoint; Meiji Seika Pharma submitted NDA in Japan.","FDA granted Fast Track and Rare Pediatric Disease Designations for ARCT-810 (OTC deficiency).","Regulatory approval received to start ARCT-032 Phase 1b study in cystic fibrosis patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001112","json":"https://secwatch.observer/filing/0001193805-23-001112.json","markdown":"https://secwatch.observer/filing/0001193805-23-001112.md","text":"https://secwatch.observer/filing/0001193805-23-001112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/0001193805-23-001112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/e618839_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:33:40.673073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2257c8abf2b26f7f133531b3edccbb47d4c7c4a","claim":"Arcturus Therapeutics Holdings Inc. reported the second quarter and six months ended June 30, 2023 results: revenue $10.5 million.","evidence_excerpt":"For the three months ended June 30, 2023, we reported revenue of $10.5 million compared with $27.1 million for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/0001193805-23-001112-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter and six months ended June 30, 2023"},{"label":"Revenue","value":"$10.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}